Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center

Key opinion leaders in hematology-oncology consider the future treatment landscape for marginal zone and follicular lymphomas and reflect on the role of chemotherapy and targeted agents as induction or maintenance.

Experts in the management of lymphoma discuss how umbralisib fits into sequencing algorithms and highlight how treatment decisions are particularly complex in MZL compared to FL.

Lori A. Leslie, MD, and Anthony Mato, MD, MSCE, comment on the potential safety and efficacy of the PI3K inhibitor umbralisib in combination with a CD20 antibody in marginal zone and follicular lymphoma.

Key opinion leaders in hematology-oncology discuss the recent UNITY-NHL trial and the FDA’s accelerated approval of umbralisib in relapsed/refractory marginal zone lymphoma and follicular lymphoma.

Expert hematologist-oncologists share insights about the role of PI3K inhibition and immunosuppression in indolent non-Hodgkin lymphoma and review the safety and efficacy of idelalisib, duvelisib, and copanlisib.

Anthony Mato, MD, MSCE, and Lori A. Leslie, MD, consider treatment options for patients with relapsed/refractory disease after first-line chemoimmunotherapy.

Key opinion leaders in hematology-oncology discuss treatment considerations for first-line chemoimmunotherapy in follicular lymphoma and marginal zone lymphoma and when to use maintenance therapy or observation.

Experts in lymphoma provide insight into factors to consider when initiating treatment and emphasize the importance of both clinical judgment and treatment guidelines like the GELF criteria when monitoring patients.

Experts in hematology-oncology build a discussion on differences in patient presentation and diagnosis of different types of indolent non-Hodgkin lymphomas such as marginal zone lymphoma and follicular lymphoma.

Lori A. Leslie, MD, and Anthony Mato, MD, MSCE, discuss the epidemiology, etiology, and risk factors for different types of lymphoma and provide key insights into those classified as indolent non-Hodgkin’s lymphoma.